Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CIPROFLOXACIN AND DEXAMETHASONE

All products: Limited Use (codes 509)

Ciprodex · DIN 02252716 · 0.3% w/v & 0.1% w/v · Otic suspension-7.5mL Pk (With Preservative)

Limited Use — Reason for Use code 509 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 509 required
Write on scriptLU code 509 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 509
Reason for Use code 509 The treatment of otitis externa in patients: - With known perforated tympanic membrane or ventilation tubes; OR - Requiring chronic therapy (i.e., more than 14 days); OR - Who have been receiving more than 7 days of topical aminoglycoside therapy without improvement, where there is concern of a resistant pathogen; OR - With documented pre-existing hearing impairment. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Ciprodex · DIN 02252716 Manufacturer: Novartis Pharma Canada Inc.; listing date 2018-06-29 Health Canada: Marketed since 2018-06-11 · brand CIPRODEX · ATC S02CA06 DEXAMETHASONE AND ANTIINFECTIVES · form Suspension · route Otic · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 0.3 %/W/V, DEXAMETHASONE 0.1 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $14.4203 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73758 · Verify on the e-Formulary ↗ (DIN 02252716)

Source record
DIN 02252716: Ciprodex Raw flags: sec12=Y, sec3=Y Item: 520404046; group id 575; item number 1529; lccId 00306; manufacturer id NOV Source form: Otic Susp-7.5mL Pk (With Preservative); strength: 0.3% w/v & 0.1% w/v Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $32.6094; ministry $14.4203 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02252716 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73758
Interchangeable products
Sandoz Ciprofloxacin/Dexamethasone · DIN 02506882 · $14.4203 Taro-Ciprofloxacin/Dexamethasone · DIN 02481901 · $14.4203
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (52:04:04 Antibiotics) and how they are covered

Matched class: 52:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FRAMYCETIN SULFATE, FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE, GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE, GENTAMICIN SULFATE, POLYMYXIN B SULFATE & BACITRACIN (ZINC), POLYMYXIN B SULFATE & GRAMICIDIN, TOBRAMYCIN, TOBRAMYCIN & DEXAMETHASONE 52:04:04 Antibiotics

FRAMYCETIN SULFATE

· 2 products · General benefit · strengths: 0.5% · Oph Oint-5g Pk, Oph Sol

FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE

· 1 products · General benefit · strengths: 5mg & 50mcg & 0.5mg/mL · Oph/Ot Sol

GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE

· 1 products · General benefit · strengths: 3mg & 1mg/mL · Oph/Ot Drops

GENTAMICIN SULFATE

· 1 products · General benefit · strengths: 0.3% · Oph Oint-3.5g Pk

POLYMYXIN B SULFATE & BACITRACIN (ZINC)

· 1 products · General benefit · strengths: 10000U & 500U/g · Oph Oint 3.5g Pk

POLYMYXIN B SULFATE & GRAMICIDIN

· 1 products · General benefit · strengths: 10000U & 0.025mg/mL · Oph/Ot Sol

TOBRAMYCIN

· 3 products · General benefit · strengths: 0.3% · Oph Oint, Oph Sol

TOBRAMYCIN & DEXAMETHASONE

· 2 products · General benefit · strengths: 0.3% & 0.1% · Oph Oint, Oph Susp

GATIFLOXACIN

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.3% w/v · Oph Sol

MOXIFLOXACIN HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5% · Oph Sol-3mL Pk (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:04:04
Full class listing Related classes: 52:04:12 Other Anti-Infectives, 52:08:92 Anti-Inflammatory Agents, Miscellaneous Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CLARITHROMYCIN · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (15), Off-Formulary Interchangeable, not an ODB benefit (9) (For additional information on the use of BIAXIN BID® in triple therapy for the treatment of H. pylori infection and active duodenal ulcer recurrence, refer to the Hp-PAC® Product Monograph.) BIAXIN® (clarithromycin for oral suspension USP) Product Monograph Master Template Template Date: September 2020 BIAXIN BID®, BIAXIN® - clarithromycin Page 4 of 107 BIAXIN® is indicated for the treatment of infections due to susceptible organisms, in the following conditions: • Upper Respiratory Tract • Pharyngitis caused by S. pyogenes (Group A ß-hemolytic streptococci). PM: https://pdf.hres.ca/dpd_pm/00078094.PDF; date DEC 17, 2024; DIN 01984853; fetched 2026-09-10 Product monograph TETRACYCLINE · Listed, not a benefit (1), General benefit (1) Indications TETRACYCLINE (tetracycline hydrochloride capsules) is indicated for infections caused by the following microorganisms: • Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, tick fevers), M. pneumoniae (PPLO, Eaton agent), agents of psittacosis and ornithosis, agents of L. venereum and G. inguinale, and the spirochetal agent of relapsing fever (B. recurrentis). PM: https://pdf.hres.ca/dpd_pm/00084169.PDF; date 2026-03-17; DIN 00580929; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE CIPRODEX® (ciprofloxacin/dexamethasone otic suspension) is indicated for the treatment of infections caused by most strains of the designated microorganisms in the specific conditions listed below: Acute Otitis Media with Otorrhea through tympanostomy tubes in pediatric patients ≥ 6 months of age due to: Aerobic, Gram-Positive: Streptococcus pneumoniae Staphylococcus aureus Aerobic, Gram-Negative: Haemophilus influenza Moraxella catarrhalis Pseudomonas aeruginosa Acute Otitis Externa in adults and pediatric patients ≥ 1 year of age due to: Aerobic, Gram-Positive: Staphylococcus aureus Aerobic, Gram-Negative: Pseudomonas aeruginosa To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRODEX and other antibacterial drugs, CIPRODEX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. CIPRODEX® Product Monograph Page 3 of 20 Geriatrics (> 65 years of age): Elderly patients may be at a higher risk of developing tendon inflammation and rupture (see WARNINGS AND PRECAUTIONS, General). Pediatrics (… https://pdf.hres.ca/dpd_pm/00041611.PDF PM date: September 27, 2017 Source product: CIPRODEX; DIN 02252716; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.